Details of the Drug

General Information of Drug (ID: DMFDERP)

Drug Name
PMID28870136-Compound-52
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 194.19
Logarithm of the Partition Coefficient (xlogp) -0.1
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1.73-28.7 mg/L [1]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.8-4.3 h [1]
Bioavailability
The bioavailability of drug is 80% [1]
Clearance
The clearance of drug is 0.078 L/h/kg [2]
Elimination
About 0.5% to 2% of a caffeine dose is found excreted in urine, as it because it is heavily absorbed in the renal tubules [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [3]
Metabolism
The drug is metabolized via the liver [2]
Vd
The volume of distribution (Vd) of drug is 0.8-0.9 L/kg [4]
Chemical Identifiers
Formula
C8H10N4O2
IUPAC Name
1,3,7-trimethylpurine-2,6-dione
Canonical SMILES
CN1C=NC2=C1C(=O)N(C(=O)N2C)C
InChI
InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
InChIKey
RYYVLZVUVIJVGH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2519
ChEBI ID
CHEBI:27732
CAS Number
58-08-2
UNII
3G6A5W338E
DrugBank ID
DB00201
TTD ID
D0H9IX
ACDINA ID
D00088

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ecto-5'-nucleotidase (CD73) TTK0O6Y 5NTD_HUMAN Inhibitor [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(E3-independent) E2 ubiquitin-conjugating enzyme OTHGS2VA UBE2O_HUMAN Post-Translational Modifications [6]
1-phosphatidylinositol 3-phosphate 5-kinase (PIKFYVE) OTO3HGAA FYV1_HUMAN Post-Translational Modifications [6]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Post-Translational Modifications [6]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 (PLCB3) OT0OMDEM PLCB3_HUMAN Post-Translational Modifications [6]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 (PLCD3) OTB22A4J PLCD3_HUMAN Post-Translational Modifications [6]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (PLCG1) OTSBQR6D PLCG1_HUMAN Post-Translational Modifications [6]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Gene/Protein Processing [7]
116 kDa U5 small nuclear ribonucleoprotein component (EFTUD2) OT3X7QG2 U5S1_HUMAN Post-Translational Modifications [6]
14-3-3 protein beta/alpha OTGBS3RF 1433B_HUMAN Post-Translational Modifications [6]
14-3-3 protein epsilon OT3WQXNA 1433E_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ecto-5'-nucleotidase (CD73) DTT NT5E 9.56E-01 0.33 0.37
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41 Suppl 1:S61-5.
2 Tarning J, Bergqvist Y, Day NP, Bergquist J, Arvidsson B, White NJ, Ashton M, Lindegardh N: Characterization of human urinary metabolites of the antimalarial piperaquine. Drug Metab Dispos. 2006 Dec;34(12):2011-9. doi: 10.1124/dmd.106.011494. Epub 2006 Sep 6.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Caffeine citrate injection FDA label
5 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
6 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
7 Caffeine reduces 11beta-hydroxysteroid dehydrogenase type 2 expression in human trophoblast cells through the adenosine A(2B) receptor. PLoS One. 2012;7(6):e38082.
8 Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.